|
Title
|
|
|
|
Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| BACKGROUND: The aim of this study is to investigate the role of octreotide long-acting release (LAR) in secondary prevention in patients with chemotherapy-induced diarrhea. METHODS: In this study, patients experiencing CID >= grade 2 received 30 mg long-acting octreotide as a monthly injection and the next chemotherapy dose was administrated with a 25% dose decrease. If no CID >= grade 2 occurred, subsequent chemotherapy doses were increased to the initial 100% values. The primary endpoint of the study was the diarrhea control rate (< grade 2) for patients receiving the optimal dose of chemotherapy for a minimum of 2 cycles. RESULTS: Twenty-nine patients were included. Ten patients experienced no improvement or ended the study very early after the first injection of octreotide LAR. Nineteen patients had a reduction in the grade of diarrhea after the first administration of octreotide LAR and a reduced chemotherapy dose. Seven of them (24%) did not reach the end of the study because of disease progression (6) or lost to follow-up (1). Ultimately, 12 patients (41%) continued the study till the end. In ten of these twelve patients, there was a significant and persisting reduction of diarrhea while receiving full-dose chemotherapy. CONCLUSIONS: This study suggests that monthly injections with long-acting octreotide might be used as a secondary prevention of chemotherapy-induced diarrhea. Its usefulness and optimal dosage in secondary prevention in combination with antidiarrheal agents needs further research. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Minerva chirurgica: rivista quindicinale di chirurgia pratica / Societa Italiana di Anestesiologia. - Torino
| |
|
Publication
|
|
|
|
Torino
:
2016
| |
|
ISSN
|
|
|
|
0026-4733
| |
|
Volume/pages
|
|
|
|
71
:2
(2016)
, p. 91-97
| |
|
ISI
|
|
|
|
000384944300004
| |
|